Let’s focus on the main game for a moment.
There have now been 15 comments submitted for consideration by the ODAC committee on Thursday.
The latest is from a Dr Tom Shannon, definitely very supportive of MSB’s application.
Dr Shannon is “excited by the prospect of a new type of therapy targeting inflammation, without the side effects of steroids and NSAIDS or even chemotherapeutic / disease modifying agents”.
He says “I was concerned to see details today of advice that may restrict access … If safety and efficacy can be achieved, even with the issues of QA around cell lines, then surely those treatments are valid.”
Definitely worth a read.
https://beta.regulations.gov/document/FDA-2020-N-1539-0037
Herro.
Let’s focus on the main game for a moment. There have now been...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
-0.055(4.89%) |
Mkt cap ! $1.221B | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.16 | $1.06 | $8.816M | 8.055M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 280000 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |